- Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". Nature medicine. 2016 In Process GET IT
- Loss of BAP1 function leads to EZH2-dependent transformation. Nature medicine. 2015 In Process GET IT
- IL10 receptor is a novel therapeutic target in DLBCLs. Leukemia. 2015 In Process GET IT
Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia.
Science translational medicine.
Times cited: 4
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation.
Times cited: 52